Trial reportNature2024
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Erratum issuedAbstract readRandomized Controlled TrialClinical Trial, Phase IIIComparative Study
In one paragraph
Trial report in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 43 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- [Systemic treatment of breast cancer: professional guideline].Magyar onkologia · 2025Guideline
- Comparative efficacy of first- versus second-line CDK4/6 inhibition in hormone receptor-positive, HER2-negative metastatic breast cancer.Breast cancer research : BCR · 2025Pooled it
- Trial
- Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.Nature medicine · 2025Trial
- Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitudeCancer biology & therapy · 2026Article
- Article
- Independent cancer research in low- and middle-income countries: why it matters and how to build it.The oncologist · 2026Review
- Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.Biomedicines · 2026Article
- Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.Breast (Edinburgh, Scotland) · 2026Observational
- Real-world insights into bone marrow carcinomatosis in metastatic breast cancer: a retrospective analysis from two large university breast cancer centers.Journal of cancer research and clinical oncology · 2026Article
- Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer.The oncologist · 2026Review
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.Nature reviews. Drug discovery · 2026Review
- Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026Review
- From authorisation to clinical practice: evolution of the use of biological medicines according to the SmPC and guidelines (2006 to 2025).European journal of clinical pharmacology · 2026Article
- Review
- Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.Breast cancer research : BCR · 2026Observational
- Beyond timing, toward precision: insights from CDK4/6 inhibitor trials in metastatic breast cancer.NPJ breast cancer · 2026Review
- Article
- Prognostic Significance of Pretreatment ¹⁸F-FDG PET/CT Parameters in Patients With ER+/HER2- Metastatic Breast Cancer Treated With CDK4/6 Inhibitors Plus Endocrine Therapy.Korean journal of radiology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
23 authors.
Gabe S SonkeDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. g.sonke@nki.nl.ORCID 0000-0001-8088-9628
Annemiek van Ommen-Nijhof *Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-1797-1060
Noor Wortelboer *Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID 0009-0006-1649-748X
Vincent van der NoortDepartment of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Astrid C P SwinkelsClinical Research Department, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.ORCID 0000-0002-0047-0948
Hedwig M BlommesteinErasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0002-5846-0531
Cristina Guerrero PaezDutch Breast Cancer Society, Utrecht, The Netherlands.
Linda MolClinical Research Department, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Aart BeekerDepartment of Medical Oncology, Spaarne Gasthuis, Hoofddorp, The Netherlands.
Karin BeelenDepartment of Medical Oncology, Rijnstate Hospital, Arnhem, The Netherlands.
Lisanne C HammingDepartment of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Joan B HeijnsDepartment of Medical Oncology, Amphia, Breda, The Netherlands.
Aafke H HonkoopDepartment of Medical Oncology, Isala Clinics, Zwolle, The Netherlands.ORCID 0000-0002-8066-2164
Paul C de JongDepartment of Medical Oncology, St Antonius Hospital, Nieuwegein, The Netherlands.
Quirine C van Rossum-SchornagelDepartment of Medical Oncology, Franciscus Gasthuis & Vlietland, Schiedam, The Netherlands.
Christa van Schaik-van de MheenDepartment of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands.
Jolien TolDepartment of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
Cathrien S Tromp-van DrielDepartment of Medical Oncology, Gelre Hospital, Apeldoorn, The Netherlands.
Suzan VrijaldenhovenDepartment of Medical Oncology, Northwest Hospital Group, Alkmaar, The Netherlands.
A Elise van Leeuwen-StokDutch Breast Cancer Research Group, BOOG Study Center, Utrecht, The Netherlands.ORCID 0000-0003-1988-4099
Inge R KoningsDepartment of Medical Oncology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Agnes JagerDepartment of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0002-7713-1450
SONIA Study Consortium
Funding
CADTH, ZIN and Medical DeltaNovartis and Gilead
Abstract
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in combination with endocrine therapy improve the outcomes of patients with hormone-receptor (HR)-positive, HER2-negative advanced breast cancer and can be used early as first-line treatment or deferred to second-line treatment
Indexed as
Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsTime-to-TreatmentAgedAntineoplastic Agents, HormonalAromatase InhibitorsDisease ProgressionEstrogen Receptor AntagonistsFemaleFulvestrantHumansMiddle AgedAntineoplastic AgentsAntineoplastic Agents, HormonalAromatase InhibitorsCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Estrogen Receptor AntagonistsFulvestrantProtein Kinase Inhibitors
Identifiers
PMID
39604725What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.